CMV viral load kinetics as surrogate endpoints after allogeneic transplantation
2020; American Society for Clinical Investigation; Volume: 131; Issue: 1 Linguagem: Inglês
10.1172/jci133960
ISSN1558-8238
AutoresElizabeth R. Duke, Brian D. Williamson, Bhavesh Borate, Jonathan L. Golob, Chiara Wychera, Terry Stevens-Ayers, Meei‐Li Huang, Nicole Cossrow, Hong Wan, T. Christopher Mast, Morgan A. Marks, Mary E.D. Flowers, Keith R. Jerome, Lawrence Corey, Peter B. Gilbert, Joshua T. Schiffer, Michael Boeckh,
Tópico(s)Parvovirus B19 Infection Studies
ResumoBACKGROUND. Viral load (VL) surrogate endpoints transformed development of HIV and hepatitis C therapeutics. Surrogate endpoints for CMV-related morbidity and mortality could advance development of antiviral treatments. Although observational data support using CMV VL as a trial endpoint, randomized controlled trials (RCTs) demonstrating direct associations between virological markers and clinical endpoints are lacking.
Referência(s)